Recent developments in the study of pyrazinamide: An update

Progress in Respiratory Research

Volumn 40, Issue , 2011, Pages 32-43

  Mitchison, Denis A ^a   Zhang, Ying ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052921093     PISSN: 14222140     EISSN: 16623932     Source Type: Book Series    
DOI: 10.1159/000324221     Document Type: Article

References (75)

1. British Thoracic and Tuberculosis Association: Short-course chemotherapy in pulmonary tuberculosis. Lancet 1976;ii:1102-1104.
2. British Thoracic Association: A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: Results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 1982;126:460-462.
3. Fox W, Ellard GA, Mitchison DA: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:S231-S279.
4. McCune RM Jr, McDermott W, Tompsett R: The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956;104:763-802.
5. McCune RM Jr, Tompsett R: Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 1956;104:737-762.
6. Mitchison DA: The action of antituberculosis drugs in short course chemotherapy. Tubercle 1985;66:219-225. (Pubitemid 16150082)
7. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH: Powerful bactericidal and sterilizing activity of a regimen containing pa-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52:1522-1524. (Pubitemid 351522025)
8. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL: Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
9. Veziris N, Ibrahim M, Lounis N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V: A onceweekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009;179:75-79.
10. Tarshis MS, Weed WA Jr: Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberculosis 1953;67:391-395.
11. McDermott W, Tompsett R: Activation of pyrazinamide and nicotinamide in acidic environment in vitro. Am Rev Tuberculosis 1954;70:748-754.
12. Heifets LB, Lindholm-Levy PJ: Is pyrazinamide bactericidal against Mycobacterium tuberculosis? Am Rev Respir Dis 1990;141:250-252. (Pubitemid 20023411)
13. McCune RM, Feldmann FM, Lambert HP, Mc-Dermott W: Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966;123:445-468.
14. McCune RM, Feldmann FM, McDermott W: Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 1966;123:469-486.
15. Zhang Y, Mitchison D: The curious characteristics of pyrazinamide: A review. Int J Tuberc Lung Dis 2003;7:6-21. (Pubitemid 36427026)
16. Scorpio A, Zhang Y: Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996;2:662-667. (Pubitemid 26191953)
17. Zhang H, Deng JY, Bi LJ, Zhou YF, Zhang ZP, Zhang CG, Zhang Y, Zhang XE: Characterization of Mycobacterium tuberculosis nicotinamidase/ pyrazinamidase. FEBS J 2008;275:753-762. (Pubitemid 351160972)
18. Fyfe PK, Rao VA, Zemla A, Cameron S, Hunter WN: Specificity and mechanism of Acinetobacter baumanii nicotinamidase: Implications for activation of the front-line tuberculosis drug pyrazinamide. Angew Chem Int Ed Engl 2009;48:9176-9179.
19. Seiner DR, Hegde SS, Blanchard JS: Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis. Biochemistry 2010, E-pub ahead of print.
20. Zhang Y, Scorpio A, Nikaido H, Sun Z: Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 1999;181:2044-2049. (Pubitemid 29164956)
21. Zhang Y, Permar S, Sun Z: Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002;51:42-49. (Pubitemid 34060132)
22. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z: Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 2003;52:790-795. (Pubitemid 37407806)
23. Huang Q, Chen ZF, Li YY, Zhang Y, Ren Y, Fu Z, Xu SQ: Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. Chemotherapy 2007;53:338-343. (Pubitemid 47415435)
24. Hu Y, Coates AR, Mitchison DA: Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2006;10:317-322.
25. Wade MM, Zhang Y: Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2006;58:936-941.
26. Wade MM, Zhang Y: Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol 2004;53:769-773. (Pubitemid 39430363)
27. Betts J, Lukey P, Robb L, McAdam R, Duncan K: Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002;43:717-731. (Pubitemid 34597265)
28. Andries K, Verhasselt P, Guillemont J, Gohlmann H, Neefs J, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V: A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227. (Pubitemid 40116230)
29. Gu P, Constantino L, Zhang Y: Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide. J Med Microbiol 2008;57:1129-1134.
30. Coleman D, Waddell S, Mitchison DA: Effects of low incubation temperatures on the bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2011;66:146-150.
31. Byrne ST, Denkin SM, Zhang Y: Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother 2007;59:313-316. (Pubitemid 47072074)
32. Somoskovi A, Wade MM, Sun Z, Zhang Y: Iron enhances the antituberculous activity of pyrazinamide. J Antimicrob Chemother 2004;53:192-196. (Pubitemid 38239949)
33. Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N: Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51:1011-1015. (Pubitemid 46355288)
34. Zimhony O, Cox JS, Welch JT, Vilcheze C, Jacobs WR Jr: Pyrazinamide inhibits the eukaryoticlike fatty acid synthetase I (FasI) of Mycobacterium tuberculosis. Nat Med 2000;6:1043-1047.
35. Boshoff HI, Mizrahi V, Barry CE 3rd: Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol 2002;184:2167-2172. (Pubitemid 34259666)
36. Cynamon MH, Speirs RJ, Welch JT: In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother 1998;42:462-463. (Pubitemid 28114468)
37. Baughn AD, Deng J, Vilcheze C, Riestra A, Welch JT, Jacobs WR Jr, Zimhony O: Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance proofing strategy. Antimicrob Agents Chemother 2010;54:5323-5328.
38. Ngo SC, Zimhony O, Chung WJ, Sayahi H, Jacobs WR Jr, Welch JT: Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob Agents Chemother 2007;51:2430-2435. (Pubitemid 47047321)
39. Zimhony O, Vilcheze C, Arai M, Welch JT, Jacobs WR Jr: Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. Antimicrob Agents Chemother 2007;51:752-754. (Pubitemid 46185301)
40. Scorpio A, Lindholm-Levy P, Heifets L, Gilman R, Siddiqi S, Cynamon M, Zhang Y: Characterization of pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997;41:540-543. (Pubitemid 27098400)
41. Konno K, Feldmann FM, McDermott W: Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 1967;95:461-469.
42. McClatchy JK, Tsang AY, Cernich MS: Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob Agents Chemother 1981;20:556-557. (Pubitemid 12239277)
43. Trivedi SS, Desai SG: Pyrazinamidase activity of Mycobacterium tuberculosis -a test of sensitivity to pyrazinamide. Tubercle 1987;68:221-224. (Pubitemid 18012661)
44. Zhang Y, Telenti A: Genetics of drug resistance in Mycobacterium tuberculosis; in Hatfull G, Jacobs WR (eds): Molecular Genetics of Mycobacteria. Washington, ASM Press, 2000, pp 235-254.
45. Sheen P, Ferrer P, Gilman RH, Lopez-Llano J, Fuentes P, Valencia E, Zimic MJ: Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 2009;89:109-113.
46. Du X, Wang W, Kim R, Yakota H, Nguyen H, Kim SH: Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. Biochemistry 2001;40:14166-14172. (Pubitemid 33081619)
47. Shenai S, Rodrigues C, Sadani M, Sukhadia N, Mehta A: Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing. Indian J Tuberculosis 2009;56:82-90.
48. Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y: PncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: Spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 2000;44:528-532. (Pubitemid 30117936)
49. Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V: Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob Agents Chemother 1999;43:1761-1763. (Pubitemid 29331263)
50. Marttila HJ, Marjamaki M, Vyshnevskaya E, Vyshnevskiy BI, Otten TF, Vasilyef AV, Viljanen MK: PncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern russia. Antimicrob Agents Chemother 1999;43:1764-1766. (Pubitemid 29331264)
51. Hewlett D Jr, Horn DL, Alfalla C: Drug-resistant tuberculosis: Inconsistent results of pyrazinamide susceptibility testing. JAMA 1995;273:916-917.
52. Pandey S, Newton S, Upton A, Roberts S, Drinkovic D: Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand. Pathology 2009;41:582-584.
53. Heifets L: Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002;51:11-12. (Pubitemid 34060127)
54. Dormandy J, Somoskovi A, Kreiswirth BN, Driscoll JR, Ashkin D, Salfinger M: Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest 2007;131:497-501. (Pubitemid 46280411)
55. Brander E: A simple way of detecting pyrazinamide resistance. Tubercle 1972;53:128-131.
56. Martin A, Cubillos-Ruiz A, Von Groll A, Del Portillo P, Portaels F, Palomino JC: Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 2008;61:123-127.
57. Martin A, Takiff H, Vandamme P, Swings J, Palomino JC, Portaels F: A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 2006;58:327-331. (Pubitemid 44294943)
58. Mirabal NC, Yzquierdo SL, Lemus D, Madruga M, Milian Y, Echemendia M, Takiff H, Martin A, Van der Stuyf P, Palomino JC, Montoro E: Evaluation of colorimetric methods using nicotinamide for rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis. J Clin Microbiol 2010;48:2729-2733.
59. Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A: Surveillance of pyrazinamide susceptibility among multidrugresistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol 2010;10:223.
60. Sekiguchi J, Nakamura T, Miyoshi-Akiyama T, Kirikae F, Kobayashi I, Augustynowicz-Kopec E, Zwolska Z, Morita K, Suetake T, Yoshida H, Kato S, Mori T, Kirikae T: Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis strains. J Clin Microbiol 2007;45:2802-2807. (Pubitemid 47417318)
61. Wade MM, Volokhov D, Peredelchuk M, Chizhikov V, Zhang Y: Accurate mapping of mutations of pyrazinamide-resistant Mycobacterium tuberculosis strains with a scanning-frame oligonucleotide microarray. Diagn Microbiol Infect Dis 2004;49:89-97. (Pubitemid 38746737)
62. Denkin S, Volokhov D, Chizhikov V, Zhang Y: Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis. J Med Microbiol 2005;54:1127-1131. (Pubitemid 41783818)
63. Minime-Lingoupou F, Pierre-Audigier C, Kassa-Kelembho E, Barilone N, Zandanga G, Rauzier J, Cadet-Daniel V, Le Faou A, Gicquel B: Rapid identification of multidrug-resistant tuberculosis isolates in treatment failure or relapse patients in Bangui, Central African Republic. Int J Tuberc Lung Dis 2010;14:782-785.
64. Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsaker T, Muthivhi T, Weyer K, Fourie PB, Grewal HM: Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008;46:3459-3464.
65. Ando H, Mitarai S, Kondo Y, Suetake T, Sekiguchi JI, Kato S, Mori T, Kirikae T: Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin Microbiol Infect 2010;16:1164-1168.
66. WHO: Anti-tuberculosis drug resistance in the world, report No 4. Geneva, WHO, 2008.
67. WHO: XDR-TB, extensively drug-resistant tuberculosis. 2006. http://www.who.int/tb/xdr/en/index.html.
68. GATB: Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb) 2001;81(suppl 1):1-52.
69. Mitchison D: The search for new sterilizing antituberculosis drugs. Front Biosci 2004;9:1059-1072. (Pubitemid 39060829)
70. Zhang Y: The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005;45:529-564. (Pubitemid 40261816)
71. Yew WW, Cynamon M, Zhang Y: Emerging drugs for the treatment of tuberculosis. Expert Opin Emerg Drugs 2011;16:1-21.
72. Nuermberger EL, Spigelman MK, Yew WW: Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010;15:764-778.
73. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E: Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52:3664-3668.
74. Andries K, Gevers T, Lounis N: Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother 2010;54:4540-4544.
75. Mitchison DA, Fourie PB: The near future: Improving the activity of rifamycins and pyrazinamide. Tuberculosis (Edinb) 2010;90:177-181.